In­smed stock sky­rock­ets on Phase 3 lung dis­ease da­ta

Shares of In­smed $IN­SM more than dou­bled Tues­day morn­ing af­ter the com­pa­ny re­leased Phase 3 da­ta in a res­pi­ra­to­ry dis­ease called bronchiec­ta­sis.

The com­pa­ny’s drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER